|
|
|
|
Vol. 300, Issue 3, 794-801, March 2002
1-Adrenoceptors in
Human Myocardium
Labor für Herzmuskelphysiologie und Molekulare Kardiologie,
Klinik III für Innere Medizin der Universität zu
Köln, Köln, Germany
In congestive heart failure patients, treatment with
-adrenoceptor
antagonists improves symptoms and decreases mortality. However,
intrinsic sympathomimetic activity of
-adrenoceptor antagonists
might be disadvantageous in chronic heart failure. The nonselective
1- and
2-adrenoceptor antagonist
bucindolol has failed to decrease mortality in clinical trials. A
putative
4-adrenoceptor, which mediates positive
inotropic effects by activation of the adenylate cyclase has been
described. Recently, this putative
4-adrenoceptor has
been identified to be a propranolol-insensitive state of the
1-adrenoceptor. The present study aimed to characterize whether bucindolol exhibits agonistic activity on this atypical
1-adrenoceptor state as one possible reason for clinical
inefficiency. For comparison
(S)-4-(3'-t-butylamino-1'-hydroxypropoxy)-benzimidozole-2 (CGP 12177), metoprolol, and nebivolol were investigated. Bucindolol did not reveal intrinsic sympathomimetic activity in electrically driven (1 Hz, 37°C), forskolin-stimulated, left ventricular papillary muscle strips (donor hearts, nonfailing; n = 5) and
in right auricular trabeculae (bypass operation; n = 4). Functional studies on the propranolol-insensitive state of
1-adrenoceptors were performed in isolated muscle
preparations after
1- and
2-adrenoceptor antagonism (propranolol, 1 µM), inhibition of
3-mediated inotropic effects
(N-nitro-L-arginine, 100 µM) and forskolin treatment (0.3 µM). Positive inotropic response
to stimulation of atypical state
1-adrenoceptors could
be demonstrated in right auricular as well as left ventricular human
myocardium (CGP 12177 treatment, 10 µM). Under these conditions, also
bucindolol, but not metoprolol and nebivolol, significantly increased
contractility (all 10 µM). In conclusion, bucindolol but not
metoprolol or nebivolol mediate positive inotropic effects in human
myocardium due to activation of atypical state
1-adrenoceptors. Thus, the agonistic activity of
bucindolol may influence outcome in heart failure patients.
This article has been cited by other articles:
![]() |
M. Floreani, G. Froldi, L. Quintieri, K. Varani, P. A. Borea, M. T. Dorigo, and P. Dorigo In Vitro Evidence That Carteolol Is a Nonconventional Partial Agonist of Guinea Pig Cardiac {beta}1-Adrenoceptors: A Comparison with Xamoterol J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 1386 - 1395. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Perlini, G. Palladini, I. Ferrero, R. Tozzi, S. Fallarini, A. Facoetti, R. Nano, F. Clari, G. Busca, R. Fogari, et al. Sympathectomy or Doxazosin, But Not Propranolol, Blunt Myocardial Interstitial Fibrosis in Pressure-Overload Hypertrophy Hypertension, November 1, 2005; 46(5): 1213 - 1218. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Bouzamondo, J.-S. Hulot, P. Sanchez, and P. Lechat Beta-blocker benefit according to severity of heart failure Eur J Heart Fail, June 1, 2003; 5(3): 281 - 289. [Abstract] [Full Text] [PDF] |
||||